Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatite, atopika - preparazzjonijiet oħra dermatoloġiċi - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck europe b.v. - tepotinib hydrochloride monohydrate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - aġenti antineoplastiċi - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - gefapixant - cough - sogħla u preparazzjonijiet kesħin - lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - limfoma, mantle-cell - inibituri tal-proteina kinase - treatment of mantle cell lymphoma (mcl).